Published in Ann N Y Acad Sci on June 01, 2004
Brain slices as models for neurodegenerative disease and screening platforms to identify novel therapeutics. Curr Neuropharmacol (2007) 1.44
Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease. BMC Neurosci (2009) 1.08
Alpha-synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. J Biol Chem (2009) 1.05
Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatr Dis Treat (2009) 1.01
Products of the Parkinson's disease-related glyoxalase DJ-1, D-lactate and glycolate, support mitochondrial membrane potential and neuronal survival. Biol Open (2014) 1.00
Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1. PLoS One (2010) 0.99
Androgens induce dopaminergic neurotoxicity via caspase-3-dependent activation of protein kinase Cdelta. Endocrinology (2009) 0.93
A brain slice culture model of viral encephalitis reveals an innate CNS cytokine response profile and the therapeutic potential of caspase inhibition. Exp Neurol (2011) 0.92
Oxidative stress defines the neuroprotective or neurotoxic properties of androgens in immortalized female rat dopaminergic neuronal cells. Endocrinology (2013) 0.83
Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease. Neurobiol Aging (2014) 0.82
Androgens exacerbate motor asymmetry in male rats with unilateral 6-hydroxydopamine lesion. Horm Behav (2011) 0.81
Specific changes of serum proteins in Parkinson's disease patients. PLoS One (2014) 0.78
Do mtDNA Mutations Participate in the Pathogenesis of Sporadic Parkinson's Disease? Curr Genomics (2009) 0.75
Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA. N Engl J Med (1999) 3.76
Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology (1995) 1.77
CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function. Bone Marrow Transplant (2010) 1.74
Brief report: inherited metabolic myopathy and hemolysis due to a mutation in aldolase A. N Engl J Med (1996) 1.74
VACTERL with the mitochondrial np 3243 point mutation. Am J Med Genet (1996) 1.72
Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism. Periprocedural safety and mid-term follow-up results of three different device occluder systems. Eur Heart J (2004) 1.69
Prevalence of smell loss in Parkinson's disease--a multicenter study. Parkinsonism Relat Disord (2009) 1.50
Atraumatic needle reduces the incidence of post-lumbar puncture syndrome. J Neurol (1994) 1.33
Biochemical and ultrastructural changes of skeletal muscle mitochondria after chronic electrical stimulation in rabbits. Pflugers Arch (1985) 1.23
Olfactory function in idiopathic Parkinson's disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients. J Neural Transm (Vienna) (2002) 1.21
Exercise-induced fibre type transitions with regard to myosin, parvalbumin, and sarcoplasmic reticulum in muscles of the rat. Pflugers Arch (1984) 1.17
Neuronal differentiation and long-term culture of the human neuroblastoma line SH-SY5Y. J Neural Transm Suppl (2007) 1.13
Transfection of mitochondria: strategy towards a gene therapy of mitochondrial DNA diseases. Nucleic Acids Res (1995) 1.11
Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett (1994) 1.10
Parkinson's disease and depression: evidence for an alteration of the basal limbic system detected by transcranial sonography. J Neurol Neurosurg Psychiatry (1997) 1.05
Olfactory function in Parkinsonian syndromes. J Clin Neurosci (2002) 1.04
Neurological disability, psychological distress, and health-related quality of life in MS patients within the first three years after diagnosis. Mult Scler (2009) 1.03
[Thunderclap headache caused by cerebellar infarction]. Schmerz (2008) 1.03
Ipsi- and contralateral fibre transformations by cross-reinnervation. A principle of symmetry. Pflugers Arch (1983) 1.01
Pathophysiology of the MELAS 3243 transition mutation. J Biol Chem (1997) 1.00
Ginsenosides Rb1 and Rg1 effects on survival and neurite growth of MPP+-affected mesencephalic dopaminergic cells. J Neural Transm (Vienna) (2003) 0.99
Olfactory function in patients with idiopathic Parkinson's disease: effects of deep brain stimulation in the subthalamic nucleus. J Neural Transm (Vienna) (2004) 0.98
Inter- and intraspecies comparisons of fibre type distribution and of succinate dehydrogenase activity in type I, IIA and IIB fibres of mammalian diaphragms. Histochemistry (1984) 0.98
Variable penetrance of a familial progressive necrotising encephalopathy due to a novel tRNA(Ile) homoplasmic mutation in the mitochondrial genome. J Med Genet (2004) 0.97
A comparison of two ATPase based schemes for histochemical muscle fibre typing in various mammals. Histochemistry (1982) 0.96
Perspectives on recent advances in the understanding and treatment of Parkinson's disease. Eur J Neurol (2009) 0.95
[Attitudes towards patient care at the end of life. A survey of directors of neurological departments]. Nervenarzt (2004) 0.94
Clinical spectrum of the MELAS mutation in a large pedigree. Acta Neurol Scand (1995) 0.93
Role of alpha adrenoceptors in the nucleus accumbens in the control of accumbal noradrenaline efflux: a microdialysis study with freely moving rats. J Neural Transm (Vienna) (2007) 0.92
New insights into the metabolic consequences of large-scale mtDNA deletions: a quantitative analysis of biochemical, morphological, and genetic findings in human skeletal muscle. J Neuropathol Exp Neurol (2000) 0.91
Levels and proteolytic processing of chromogranin A and B and secretogranin II in cerebrospinal fluid in neurological diseases. J Neural Transm (Vienna) (1998) 0.91
Kinetic tremor in Parkinson's disease--an underrated symptom. J Neural Transm (Vienna) (2006) 0.91
Olfactory bulb volumes in patients with idiopathic Parkinson's disease a pilot study. J Neural Transm (Vienna) (2005) 0.90
A mild juvenile variant of type IV glycogenosis. Brain Dev (1992) 0.90
Baroreflex sensitivity and power spectral analysis in different extrapyramidal syndromes. J Neural Transm (Vienna) (2008) 0.90
HLA typing and Parkinson's disease. Eur Neurol (2003) 0.90
Cricopharyngeal achalasia is a common cause of dysphagia in patients with mtDNA deletions. Neurology (2001) 0.89
Cerebral vasculitis with multiple infarcts caused by lyme disease. Cerebrovasc Dis (2003) 0.89
Neurological multisystem manifestation in multiple symmetric lipomatosis: a clinical and electrophysiological study. Muscle Nerve (1995) 0.89
[Adherence to neurologic treatment. Lessons from multiple sclerosis]. Nervenarzt (2008) 0.89
Relationships between early alterations in parvalbumins, sarcoplasmic reticulum and metabolic enzymes in chronically stimulated fast twitch muscle. Pflugers Arch (1983) 0.88
Chronic alcohol consumption and cerebral indices of oxidative stress: is there a link? Alcohol Clin Exp Res (2001) 0.88
[Multiple sclerosis management system 3D. Moving from documentation towards management of patients]. Nervenarzt (2012) 0.88
Mutation analysis in myophosphorylase deficiency (McArdle's disease). Ann Neurol (1998) 0.88
A method for quantitative extraction of enzymes and metabolites from tissue samples in the milligram range. J Histochem Cytochem (1982) 0.87
Metabolic patterns in malignant gliomas. J Neurooncol (1995) 0.87
Rotigotine transdermal system for perioperative administration. J Neural Transm (Vienna) (2006) 0.87
Fibre type specific transformations in the enzyme activity pattern of rat vastus lateralis muscle by prolonged endurance training. Pflugers Arch (1983) 0.87
Modafinil for excessive daytime sleepiness in myotonic dystrophy. Neurology (2001) 0.87
Treatment of Parkinson's disease in the advanced stage. J Neural Transm (Vienna) (2013) 0.86
Chronic progressive external ophthalmoplegia is associated with a novel mutation in the mitochondrial tRNA(Asn) gene. Biochem Biophys Res Commun (1994) 0.86
Effects of low frequency electrical stimulation on enzyme and isozyme patterns of dystrophic mouse muscle. FEBS Lett (1981) 0.85
Depression and care-dependency in Parkinson's disease: results from a nationwide study of 1449 outpatients. Parkinsonism Relat Disord (2011) 0.85
Immunohistochemical, volumetric, and functional neuroimaging studies in patients with idiopathic Parkinson's disease. J Neurol Sci (2009) 0.85
Focal myositis of the temporal muscle. Muscle Nerve (1993) 0.85
The TaClo concept: 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo), a new toxin for dopaminergic neurons. J Neural Transm Suppl (1995) 0.84
Circadian cortisol, depressive symptoms and neurological impairment in early multiple sclerosis. Psychoneuroendocrinology (2011) 0.84
Cranial MRI and CT in patients with left atrial myxoma. Neuroradiology (1992) 0.84
Pneumonia and in-hospital mortality in the context of neurogenic oropharyngeal dysphagia (NOD) in stroke and a new NOD step-wise concept. J Neurol (2010) 0.84
[Dysphagia diagnostics and therapy of acute stroke: federal survey of certified stroke units]. Nervenarzt (2012) 0.84
Differentiation of parkinsonian syndromes according to differences in executive functions. J Neural Transm (Vienna) (2003) 0.84
Hypertrophic cardiomyopathy with mitochondrial myopathy. A new phenotype of complex II defect. Jpn Heart J (1993) 0.83
Rapid reduction in parvalbumin concentration during chronic stimulation of rabbit fast twitch muscle. FEBS Lett (1983) 0.83
Metabolic changes in patients with mitochondrial myopathies and effects of coenzyme Q10 therapy. J Neurol (1998) 0.83
Valsalva manoeuvre in patients with different Parkinsonian disorders. J Neural Transm (Vienna) (2009) 0.83
Contrast-enhanced transcranial color-coded duplexsonography in stroke patients with limited bone windows. AJNR Am J Neuroradiol (2000) 0.83
A comparative microphotometric study of succinate dehydrogenase activity levels in type I, IIA and IIB fibres of mammalian and human muscles. Histochemistry (1982) 0.82
Pergolide protects dopaminergic neurons in primary culture under stress conditions. J Neural Transm (Vienna) (2002) 0.82
Adult-onset glycogen storage disease type II: phenotypic and allelic heterogeneity in German patients. Neurogenetics (1998) 0.82
Mitochondrial DNA mutations in multiple symmetric lipomatosis. Mol Cell Biochem (1997) 0.82
Becker muscular dystrophy: detection of unusual disease courses by combined approach to dystrophin analysis. Muscle Nerve (1992) 0.81
Multisystem triglyceride storage disorder without ichthyosis in two siblings. Acta Paediatr (1994) 0.81
Beta-oxidation enzymes in normal human muscle and in muscle from a patient with an unusual form of myopathic carnitine deficiency. Muscle Nerve (1985) 0.81
Multiple symmetric lipomatosis: abnormalities in complex IV and multiple deletions in mitochondrial DNA. Neurology (1994) 0.81
On the stability of key enzymes of energy metabolism in muscle biopsies. Enzyme (1990) 0.81
Coenzyme Q10 reduces the toxicity of rotenone in neuronal cultures by preserving the mitochondrial membrane potential. Biofactors (2003) 0.81
Effects of chronic stimulation on the metabolic heterogeneity of the fibre population in rabbit tibialis anterior muscle. J Physiol (1984) 0.81
The cold hand sign in multiple system atrophy: skin perfusion revisited. J Neural Transm (Vienna) (2010) 0.80
Analysis of the polymorphic prion protein gene codon 129 in idiopathic Parkinson's disease. J Neural Transm (Vienna) (2005) 0.80
Long-term behavioural effects of TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline) after subchronic treatment in rats. J Neural Transm Suppl (1995) 0.80
Emetine-induced myopathy and carnitine deficiency. J Neurol (1990) 0.80
The DONPAD-study--treatment of dementia in patients with Parkinson's disease with donepezil. J Neural Transm Suppl (2006) 0.80
Decreased parvalbumin contents in skeletal muscles of C57BL/6J(dy2J/dy2J) dystrophic mice. Muscle Nerve (1985) 0.80
Rapidly progressive course of very late onset multiple sclerosis presenting with Parkinsonism: case report. Mult Scler (2010) 0.80
Mitochondrial myopathy due to complex III deficiency with normal reducible cytochrome b concentration. Arch Neurol (1986) 0.80
Influence of direct low frequency stimulation on contractile properties of denervated fast-twitch rabbit muscle. Pflugers Arch (1985) 0.80
A rapid fluorometric method for the determination of carnitine palmitoyltransferase. Anal Biochem (1993) 0.80
Bromal-derived tetrahydro-beta-carbolines as neurotoxic agents: chemistry, impairment of the dopamine metabolism, and inhibitory effects on mitochondrial respiration. Bioorg Med Chem (2000) 0.80
Mitochondrial DNA in migraine with aura. Neurology (1996) 0.80
Education research: cognitive performance is preserved in sleep-deprived neurology residents. Neurology (2009) 0.80
Alzheimer's Disease: Differences of Transdermal versus Oral Treatment on Caregiving Time. Dement Geriatr Cogn Dis Extra (2012) 0.80
A rapid and sensitive PCR screening method for point mutations associated with mitochondrial encephalomyopathies. Biochem Biophys Res Commun (1994) 0.79
Processing of artificial peptide-DNA-conjugates by the mitochondrial intermediate peptidase (MIP). Biol Chem (1999) 0.79
Noninvasive assessment of the circle of Willis in cerebral ischemia: the potential of CT angiography and contrast-enhanced transcranial color-coded duplexsonography. Cerebrovasc Dis (1999) 0.79
TaClo as a neurotoxic lead: improved synthesis, stereochemical analysis, and inhibition of the mitochondrial respiratory chain. J Neural Transm Suppl (1995) 0.79
The corpus callosum in communicating and noncommunicating hydrocephalus. Neuroradiology (1995) 0.79
Protection of dopaminergic neurons in primary culture by lisuride. J Neural Transm (Vienna) (2002) 0.78
High-dose therapy with ropinirole in patients with Parkinson's disease. J Neural Transm (Vienna) (2001) 0.78